Lung transplantation: selection of patients and analysis of outcome.
Lung transplantation is an important option for patients with respiratory failure and limited life expectancy. Herein we review the current indications for and outcome after lung transplantation. These results are compared with the natural history of various respiratory diseases, estimated from available databases. Candidates for lung transplantation are generally younger than 60 years of age, have a limited life expectancy because of end-stage lung disease, and have no other major organ dysfunction. Single lung transplantation is performed most commonly for emphysema, pulmonary fibrosis, and pulmonary hypertension. Survival after single lung transplantation is approximately 70% at 1 year, 60% at 2 years, and 40% at 3 years. The median duration of survival for patients with end-stage lung diseases ranges from approximately 2 to 6 years, with wide variation based on the diagnosis and severity of illness. Currently, prolongation of the average survival has not been clearly substantiated after lung transplantation. Further evaluation of outcomes, functional status, and quality of life after lung transplantation is necessary.
Peters
S G
SG
Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Minnesota 55905, USA.
McDougall
J C
JC
Scott
J P
JP
Midthun
D E
DE
Jowsey
S G
SG
D006801:Humans; D016040:Lung Transplantation / Q000592:standards*; D018579:Patient Selection; D016019:Survival Analysis; D016896:Treatment Outcome